Trial Profile
Phase II Study of Pembrolizumab in Combination With BCG After Endoscopic Ablation for Patients With High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma Unfit or Unwilling to be Treated With Nephroureterectomy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2023
Price :
$35
*
At a glance
- Drugs BCG (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 04 Jan 2023 Status changed from not yet recruiting to discontinued.
- 20 Nov 2017 New trial record